232 related articles for article (PubMed ID: 22761399)
21. MicroRNA-21, up-regulated by arsenite, directs the epithelial-mesenchymal transition and enhances the invasive potential of transformed human bronchial epithelial cells by targeting PDCD4.
Luo F; Ji J; Liu Y; Xu Y; Zheng G; Jing J; Wang B; Xu W; Shi L; Lu X; Liu Q
Toxicol Lett; 2015 Jan; 232(1):301-9. PubMed ID: 25445583
[TBL] [Abstract][Full Text] [Related]
22. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
Cho HC; Lai CY; Shao LE; Yu J
Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
[TBL] [Abstract][Full Text] [Related]
23. miRomics and Proteomics Reveal a miR-296-3p/PRKCA/FAK/Ras/c-Myc Feedback Loop Modulated by HDGF/DDX5/β-catenin Complex in Lung Adenocarcinoma.
Fu Q; Song X; Liu Z; Deng X; Luo R; Ge C; Li R; Li Z; Zhao M; Chen Y; Lin X; Zhang Q; Fang W
Clin Cancer Res; 2017 Oct; 23(20):6336-6350. PubMed ID: 28751441
[No Abstract] [Full Text] [Related]
24. Proteome analysis for downstream targets of oncogenic KRAS--the potential participation of CLIC4 in carcinogenesis in the lung.
Okudela K; Katayama A; Woo T; Mitsui H; Suzuki T; Tateishi Y; Umeda S; Tajiri M; Masuda M; Nagahara N; Kitamura H; Ohashi K
PLoS One; 2014; 9(2):e87193. PubMed ID: 24503901
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues.
Liang H; Zhang J; Shao C; Zhao L; Xu W; Sutherland LC; Wang K
J Exp Clin Cancer Res; 2012 Apr; 31(1):36. PubMed ID: 22537942
[TBL] [Abstract][Full Text] [Related]
26. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
27. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
[TBL] [Abstract][Full Text] [Related]
28. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
[TBL] [Abstract][Full Text] [Related]
29. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations.
Hiramatsu M; Ninomiya H; Inamura K; Nomura K; Takeuchi K; Satoh Y; Okumura S; Nakagawa K; Yamori T; Matsuura M; Morikawa T; Ishikawa Y
Lung Cancer; 2010 Oct; 70(1):94-102. PubMed ID: 20117855
[TBL] [Abstract][Full Text] [Related]
30. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases.
Monaco SE; Nikiforova MN; Cieply K; Teot LA; Khalbuss WE; Dacic S
Hum Pathol; 2010 Jan; 41(1):94-102. PubMed ID: 19740513
[TBL] [Abstract][Full Text] [Related]
31. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
32. The function and significance of SELENBP1 downregulation in human bronchial epithelial carcinogenic process.
Zeng GQ; Yi H; Zhang PF; Li XH; Hu R; Li MY; Li C; Qu JQ; Deng X; Xiao ZQ
PLoS One; 2013; 8(8):e71865. PubMed ID: 23977169
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas.
Woo T; Okudela K; Yazawa T; Wada N; Ogawa N; Ishiwa N; Tajiri M; Rino Y; Kitamura H; Masuda M
Lung Cancer; 2009 Sep; 65(3):355-62. PubMed ID: 19162366
[TBL] [Abstract][Full Text] [Related]
34. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.
Baldelli E; Bellezza G; Haura EB; Crinó L; Cress WD; Deng J; Ludovini V; Sidoni A; Schabath MB; Puma F; Vannucci J; Siggillino A; Liotta LA; Petricoin EF; Pierobon M
Oncotarget; 2015 Oct; 6(32):32368-79. PubMed ID: 26468985
[TBL] [Abstract][Full Text] [Related]
35. KRAS mutation-positive bronchial surface epithelium (BSE)-type lung adenocarcinoma with strong expression of TTF-1: a case providing a further insight as for the role of TTF-1 in the oncogenesis.
Takanashi Y; Tajima S; Hayakawa T; Neyatani H; Funai K
Int J Clin Exp Pathol; 2015; 8(11):15338-43. PubMed ID: 26823891
[TBL] [Abstract][Full Text] [Related]
36. Resistance to mutant KRAS
Muraki N; Yamada M; Doki H; Nakai R; Komeda K; Goto D; Kawabe N; Matsuoka K; Matsushima M; Kawabe T; Tanaka I; Morise M; Shay JW; Minna JD; Sato M
Exp Cell Res; 2022 May; 414(1):113053. PubMed ID: 35149086
[TBL] [Abstract][Full Text] [Related]
37. Reconstructing targetable pathways in lung cancer by integrating diverse omics data.
Balbin OA; Prensner JR; Sahu A; Yocum A; Shankar S; Malik R; Fermin D; Dhanasekaran SM; Chandler B; Thomas D; Beer DG; Cao X; Nesvizhskii AI; Chinnaiyan AM
Nat Commun; 2013; 4():2617. PubMed ID: 24135919
[TBL] [Abstract][Full Text] [Related]
38. Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler.
Sasaki H; Okuda K; Kawano O; Endo K; Yukiue H; Yokoyama T; Yano M; Fujii Y
Oncol Rep; 2007 Sep; 18(3):623-8. PubMed ID: 17671710
[TBL] [Abstract][Full Text] [Related]
39. A fully integrated, automated and rapid detection system for KRAS mutations.
Ureshino N; Sueoka-Aragane N; Nakamura T; Sato A; Komiya K; Iwanaga K; Mitsuoka M; Takeda Y; Hayashi S; Sueoka E; Kimura S
Oncol Rep; 2011 Sep; 26(3):609-13. PubMed ID: 21667033
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.
Okudela K; Yazawa T; Woo T; Sakaeda M; Ishii J; Mitsui H; Shimoyamada H; Sato H; Tajiri M; Ogawa N; Masuda M; Takahashi T; Sugimura H; Kitamura H
Am J Pathol; 2009 Aug; 175(2):867-81. PubMed ID: 19608870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
